טוען...
Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro
Human cytomegalovirus (HCMV) infection and reactivation are a major cause of morbidity in immune-suppressed patients. Interestingly, epidemiological studies have shown that patients administered the mammalian target of rapamycin (mTOR) inhibitor, sirolimus (rapamycin), exhibit more favourable outcom...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Society for General Microbiology
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4165932/ https://ncbi.nlm.nih.gov/pubmed/24986086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1099/vir.0.066332-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|